Detecting pancreatic high-grade dysplasia
AssigneeMayo Foundation for Medical Education and Research
InventorsDavid A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney
Life of this patent
Estimating the term…
Abstract
Provided herein is technology for pancreatic high-grade dysplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC).
Claims21
A method of screening for pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC) in a sample obtained from a subject, the method comprising:
- a) assaying a methylation state of a marker in a sample obtained from a subject;
- and
- b) identifying the subject as having pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC) when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC), wherein the marker comprises a base in a differentially methylated region (DMR) selected from BMP3, NDRG4, ABCB1, AK055957, C13ORF18, CD1D, CLEC11A, DLX4, ELMO1, EMX1, FER1L4, FRMD4A, GRIN2D, HOXA1, LRRC4, PRKCB, SP9, ST6GAL2, ST8SIA1, TBX15, VWC2, and ZNF781.
12-39. (canceled)
A kit comprising a sample collector for obtaining a sample from a subject;
- reagents for isolating a nucleic acid from the sample;
- a bisulfite reagent;
- and one or more oligonucleotides comprising a sequence selected from the group consisting of SEQ ID NO:
- 1-48.
41-43. (canceled)
A method for characterizing a biological sample comprising:
- measuring a methylation level of a CpG site for two or more genes selected from either
- BMP3, NDRG4, ABCB1, AK055957, C13ORF18, CD1D, CLEC11A, DLX4, ELMO1, EMX1, FER1L4, FRMD4A, GRIN2D, HOXA1, LRRC4, PRKCB, SP9, ST6GAL2, ST8SIA1, TBX15, VWC2, and ZNF781 in a biological sample of a human through
- treating genomic DNA in the biological sample with bisulfite;
- amplifying the bisulfite-treated genomic DNA using a set of primers for the selected two or more genes;
- and
- determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR.
Dependencies are inferred from the claim text.